Abstract
It is obviously irrelevant to discuss pharmacologic characteristics of Corynebacterium parvum, this being not a biochemically defined agent, but a killed freeze-dried bacteria, with a very complex membrane. This bacteria is not submitted to metabolic processes like a drug. It first behaves like a very complicated group of antigens. In addition, it possesses nonspecific stimulating properties on the reticuloendothelial system, and its effects depend upon the state of the immunosystem at the time it is injected. For these reasons, it seems likely that the fate of C parvum in the body, like other complex microorganisms, will never be described in terms of pharmacology. Nevertheless, some data grossly relevant to this field can be summarized here.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Barth RF, Singla O (1978) Organ distribution of technetium-99m-labeled Corynebacterium parvum in normal and tumor-bearing mice. Cancer Res 38:32–37
Creasman WT, Gall SA, Blessing JA, Schmidt HJ, Abu-Ghazaleh S, Whisnant JK, DiSaia PJ (1979) Chemoimmunotherapy in the management of primary stage III ovarian cancer: A gynecologic oncology group study. Cancer Treat Rep 63:319–323
Fisher B, Linta J, Hanlon J, Saffer E (1978) Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. V. Comparison of the effects of tilorone hydrochloride, levamisole, methanol-soluble fraction of Mycobacterium butyricum, BCG, and a nonviable aqueous ether extract of Brucella abortus preparation in treatment of mice with tumors. J Natl Cancer Inst 60:391–398
Fisher B, Wolmark N, Saffer E, Fisher ER (1975) Inhibitory effect of prolonged Corynebacterium parvum and cyclophosphamide administration on the growth of established tumors. Cancer 35:134–143
Foster RS Jr, McPherson BR, Browdie DA (1977) Effect of Corynebacterium parvum on colony-stimulating factor and granulocyte-macrophage colony formation. Cancer Res 37:1349–1355
Hattori T, Yamagata S (1975) Combination of non-specific immunopotentiation with Corynebacterium parvum liquefaciens and chemotherapy in tumor-bearing mice. Gann 66:711–715
Israel L (1974) Non-specific immuno-stimulation in bronchogenic cancer. Scand J Respir Dis [suppl] 89:95–105
Israel L A randomized study of chemotherapy versus chemotherapy and immune therapy with Corynebacterium parvum in advanced breast cancer. In: Ambrosiana Milano (ed) Conferences, symposium, workshops of the XIth International Cancer Congress, Florence 1974, vol I, pp 222–223
Israel L (1975) Report on 414 cases of human tumors treated with Corynebacteria. In: Halpern B (ed) Corynebacterium parvum. Plenum, New York London, pp 389–401
Israel L (1976) Immunochemotherapy with Corynebacterium parvum in disseminated cancer. Ann NY Acad Sci 277:241–251
Israel L, Depierre A (1976) Combination of Corynebacterium parvum and cytostatic drugs in disseminated human cancers. Chemotherapy 7:351–354
Israel L, Edelstein R (1975) Nonspecific immunostimulation with Corynebacterium parvum in human cancer. In: The Williams & Wilkins Company (ed) Immunological aspects of neoplasia. The University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, pp 485–504
Israel L, Edelstein R, Depierre A, Dimitrov N (1975) Daily intravenous infusions of Corynebacterium parvum in twenty patients with disseminated cancer: A preliminary report of clinical and biologic findings. J Natl Cancer Inst 55:29–33
Israel L, Halpern B (1972) Le Corynebacterium parvum dans les cancers avancés. Nouv Presse Med 1:19–23
Israel L, Samak R Monocyte chemotactism as related to stage and clinical situation in cancer patients. 4th Annual Meeting of the Medical Oncology Society. Abstract 58, Nice 1978, p 15
Israel L, Samak R A modified skin window technique as a staging tool in solid tumors. Correlation between nonspecific monocyte mobilization in vivo and spread of disease. Proceedings of the 70th Annual Meeting of the AACR. Abstract 195, New Orleans, May 16–19, 1979, p 49
Scott MT (1979) Analysis of the principles underlying chemo-immunotherapy of mouse tumours. I. Treatment with cyclophosphamide followed by Corynebacterium parvum. Cancer Immunol Immunother 6:107–112
Scott MT (1979) Analysis of the principles underlying chemo-immunotherapy of mouse tumours. II. Treatment with Corynebacterium parvum followed by cyclophosphamide. Cancer Immunol Immunother 6:113–119
Scott MT, Milas L (1977) The distribution and persistence in vivo of Corynebacterium parvum in relation to its antitumor activity. Cancer Res 37:1673–1679
Suit HD, Sedlacek R, Wagner M, Orsi L (1975) Radiation response of C3H fibrosarcoma enhanced in mice stimulated by Corynebacterium parvum. Nature 255:493–494
Tuttle RL, North RJ (1975) Mechanisms of antitumor action of Corynebacterium parvum: Nonspecific tumor cell destruction at site of an immunologically mediated sensitivity reaction to C. parvum. J Natl Cancer Inst 55:1403–1411
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Israel, L. (1980). Some “Pharmacologic” Data About Corynebacterium Parvum. In: Mathé, G., Muggia, F.M. (eds) Cancer Chemo- and Immunopharmacology. Recent Results in Cancer Research, vol 75. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81491-4_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-81491-4_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81493-8
Online ISBN: 978-3-642-81491-4
eBook Packages: Springer Book Archive